{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:47:19Z","timestamp":1785365239355,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.chest.2020.03.001","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T05:09:57Z","timestamp":1593666597000},"page":"17-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Causes of Poor Medication Adherence in Sarcoidosis"],"prefix":"10.1016","volume":"158","author":[{"given":"Marc A.","family":"Judson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2020.03.001_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.chest.2020.01.026","article-title":"Association of medication adherence and clinical outcomes in sarcoidosis","volume":"158","author":"Sharp","year":"2020","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2020.03.001_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2020.03.001_bib3","doi-asserted-by":"crossref","first-page":"15026","DOI":"10.1038\/npjpcrm.2015.26","article-title":"Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study","volume":"25","author":"Cooper","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2020.03.001_bib4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/cen.12991","article-title":"Glucocorticoid therapy for adrenal insufficiency: nonadherence, concerns and dissatisfaction with information","volume":"84","author":"Chapman","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.chest.2020.03.001_bib5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2133.2010.09877.x","article-title":"Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy","volume":"163","author":"Arena","year":"2010","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.chest.2020.03.001_bib6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.crohns.2014.08.013","article-title":"Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in inflammatory bowel disease","volume":"8","author":"Mountifield","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"1","key":"10.1016\/j.chest.2020.03.001_bib7","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"10.1016\/j.chest.2020.03.001_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2020.03.001_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.chest.2020.03.001_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2020.03.001_bib11","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.chest.2020.03.001_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2013.11.019","article-title":"The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial","volume":"108","author":"Judson","year":"2014","journal-title":"Respir Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220304347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220304347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:22:05Z","timestamp":1757924525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220304347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0012369220304347"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.03.001","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Causes of Poor Medication Adherence in Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.01.026","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}